Amgen, a global biopharmaceutical giant, has just launched its first Scholars Program in India with an inaugural cohort of just 10 undergraduate students, signaling a focused, long-term bet on AI talent for drug discovery. The program aims to cultivate specialized skills directly, rather than competing for existing experts. The program at the International Institute of Information Technology (IIIT) Hyderabad includes scholars from India, Vietnam, Qatar, and Dubai, according to Express Pharma.
Global pharmaceutical companies increasingly rely on advanced AI/ML capabilities for drug discovery. However, the highly specialized talent needed to integrate these technologies is scarce and requires significant long-term cultivation.
Strategic, localized programs like Amgen's in India are likely to become a critical model for biopharma companies seeking to cultivate specialized AI/ML talent and accelerate R&D pipelines globally, despite their initially modest scale.
- Amgen launched its first Scholars Program in India at the International Institute of Information Technology (IIIT) Hyderabad, according to Express Pharma.
- The inaugural cohort comprises 10 undergraduate scholars from India, Vietnam, Qatar, and Dubai, as reported by BioSpectrum India.
- This two-month residential program focuses on AI, machine learning, and scientific research, states Telangana Today.
- Amgen supports this program through summer 2027.
- Scholars will explore artificial intelligence and machine learning applications in fundamental sciences, drug design, healthcare, cheminformatics, and genomics.
Cultivating Future AI Leaders for Drug Discovery
Scholars will explore artificial intelligence and machine learning applications across fundamental sciences, drug design, healthcare, cheminformatics, and genomics, according to Express Pharma. The broad academic focus demonstrates Amgen's investment in both theoretical and exploratory AI/ML aspects for drug discovery.
Selection for the program emphasized academic excellence, research aptitude, and motivation for doctoral studies, as reported by BioSpectrum India. The criteria suggests Amgen is shaping future research leaders, not just filling immediate skill gaps.
Amgen supports the program through summer 2027. The long-term commitment, coupled with participation in a regional Amgen Scholars Symposium in Tokyo in August 2026, integrates the cohort into a broader global scientific network, fostering cross-cultural collaboration.
Amgen's multi-year investment and comprehensive program structure demonstrate a clear strategy to build a specialized global talent pipeline essential for driving future AI-driven breakthroughs in biopharmaceutical research.
Amgen's decision to launch its first Scholars Program in India, specifically at IIIT Hyderabad, represents a strategic shift. It aims to leverage emerging technical talent hubs beyond traditional Western centers for foundational AI/ML development in drug discovery. The move reflects a calculated bet on a globally distributed talent pool.
By focusing on fundamental sciences alongside drug design, cheminformatics, and genomics, Amgen signals a deeper, more foundational approach. The focus goes beyond simply adopting current applied technologies. The approach indicates an investment in the theoretical and exploratory aspects of AI/ML for drug discovery.
This initiative marks Amgen's strategic expansion into a key global talent market. It establishes a new hub for advanced scientific training in AI and machine learning. The approach could redefine industry talent strategies for biopharma.
Implications for Biopharma Talent Strategies
This targeted approach by Amgen, focusing on a small, highly selective cohort, suggests a future model for talent acquisition in specialized fields. Companies might increasingly invest in direct cultivation rather than relying solely on competitive hiring. Direct cultivation could secure a pipeline of future AI/ML experts.
The success of this Amgen Scholars Program in India could validate the strategy of developing long-term talent in specific global regions. Other pharmaceutical firms may follow this model, leading to more geographically diverse research collaborations. Such programs could decentralize AI/ML drug discovery expertise.
This strategy positions Amgen to influence the direction of AI/ML in drug discovery over the next decade. By 2027, the outcomes from this initial cohort could set a new benchmark for biopharma talent development.
What are the eligibility criteria for the Amgen Scholars Program in India?
To be eligible for the Amgen Scholars Program in India, applicants must typically be undergraduate students demonstrating academic excellence and a strong research aptitude. A key requirement includes a clear motivation for pursuing doctoral studies and an interest in applying artificial intelligence and machine learning to drug discovery.
When is the application deadline for the Amgen Scholars Program 2026?
The application deadline for the Amgen Scholars Program in India for 2026 would precede the program's start, which is a two-month residential period. Specific dates are usually announced annually on the IIIT Hyderabad website or Amgen's official program pages. Prospective applicants should monitor these sites for precise timing.
What are the benefits of participating in the Amgen Scholars Program?
Participants in the Amgen Scholars Program gain hands-on research experience in AI and machine learning applied to drug discovery and fundamental sciences. Scholars also attend seminars, participate in networking events, and present their research at a regional symposium, such as the one planned for Tokyo in August 2026. This fosters global scientific connections.
